MALVERN, Pa., April  06, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the &#34;Company&#34;), a medical technology company focused on designing, developing, and marketing products that improve the quality of life

STIM

Neuronetics Announces Chief Financial Officer Transition

Neuronetics' CFO Resignation and Guidance Reaffirmation: Impact Analysis

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>MALVERN, Pa., April  06, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the &amp;#34;Company&amp;#34;), a medical technology company focused on designing, developing, and marketing products that improve the quality of life</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Neuronetics&#039; CFO, Steven E. Pfanstiel, will leave the company on May 1, 2026. The company reaffirmed its previous financial guidance, which may help stabilize investor sentiment amid leadership changes.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CFO Steven E. Pfanstiel resigns effective May 1, 2026.</li><li>Company launches search for new CFO; no disputes noted.</li><li>Neuronetics reaffirms guidance from March 17, 2026 earnings call.</li><li>NeuroStar offers advanced treatment for major depressive disorder.</li><li>Neuronetics emphasizes mental health importance and growth in treatment options.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Greenbrook TMS Inc. (N/A)</strong>: Operates treatment centers crucial for STIM&#039;s NeuroStar therapy growth.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments, as leadership changes can significantly affect strategic direction and investor sentiment in Neuronetics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CFO resignation could create short-term volatility in stock price.</li><li>Reaffirmation of financial guidance may restore investor confidence.</li><li>Successful transition to a new CFO could solidify long-term stability.</li><li>Market demand for NeuroStar treatments remains a positive driver.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Steven E. Pfanstiel will depart as CFO on May 1, 2026.</li><li>Guidance reaffirmed from the March 17, 2026 earnings call.</li><li>Neuronetics&#039; NeuroStar is the top TMS therapy for major depressive disorder.</li><li>Neuronetics also operates Greenbrook treatment centers across the U.S.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in STIM as stability persists, with a potential upward price movement in the short-term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>MALVERN, Pa., April  06, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/STIM">STIM</a>) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar&#xAE; Advanced Therapy, today announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company. He will remain with the Company through May 1, 2026 to support an orderly transition. Mr. Pfanstiel's decision to resign is not the result of any dispute or disagreement with the Company or the Company's management or Board on any matter relating to the Company's operations, policies, or practices. The Company has launched a search to identify Mr. Pfanstiel's replacement.<br></br><br></br>In conjunction with today&#39;s announcement, Neuronetics reaffirmed the financial guidance it provided during its fourth quarter 2025 earnings call on March 17, 2026.<br></br><br></br><strong>About Neuronetics</strong><br></br></p>  <p>Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. ("Greenbrook") treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder ("MDD") and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation ("TMS") treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO&#xAE; (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.<sup>1</sup></p>  <p>The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit <a href="https://www.globenewswire.com/Tracker?data=VkfPNTkQGHqKyVPLdQ7jiTuKglBoHal-8eJEtpn7L270iGhUwgNh8QzDM-XzFoQ-N1B2Gh5Br9uESXnNUegaMcZBnezykOSNr9fqN3FaDCBeWPlTmDdQAzisJa3oLA3H8VuKUQjZJWaqdk3OSVNqzK7VtmS5zxGUkcUEFbeR0bcRq-xlTu0buFepr27FPLYlkWJaBad8DzuF4SXZ9gGESZ72wzv2Mdx7w8sVu5DQK1c=" rel="nofollow" target="_blank"><strong>NeuroStar.com</strong></a>.</p>  <p>"Safe harbor" statement under the Private Securities Litigation Reform Act of 1995:</p>  <p>Certain statements in this press release, including the documents incorporated by reference herein, include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and "forward-looking information" within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "may," "will," "would," "should," "expect," "plan," "design," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "outlook" or "continue" as well as the negative of these terms and similar expressions. These statements include those relating to the Company's business outlook and current expectations for upcoming quarters and fiscal years, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to maintain positive cash flow. For a discussion of these and other related risks, please refer to the Company's recent filings with the SEC, which are available on the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>, including, without limitation, the factors described under the heading "Risk Factors" in Neuronetics' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company's expectations.</p>  <p>Investor Contact:</p>  <p>Mike Vallie or Mark Klausner<br></br>ICR Healthcare<br></br>443-213-0499<br></br><a href="https://www.globenewswire.com/Tracker?data=axKWPGBvwVLbBpMLBd5IweiFJYRaSF2l_zqEE52VHWSX1eprTRHhvFTrduqXc2eS3vi5dfaF9SofGLlhxlpz549iPtOgt_e7iMrhqX53R9hXVYbHkCSfXkogxPIAkT7arsuI-hYVXoaT-LqXv-zO6ky7UK4SczHq-Mde6HtXTmr6lBKNxmvs2ouvIYchKMsLbLQrThaF7ext78myEeLQQh9QwsApEMhcGwNTq0zKgI40nnYyOvaLYytenvckMVC_-D-6_YW70-R2H-wbsly38A==" rel="nofollow" target="_blank"><strong>ir@neuronetics.com</strong></a></p>  <p>Media Contact:</p>  <p>EvolveMKD<br></br>646-517-4220<br></br><a href="https://www.globenewswire.com/Tracker?data=VkfPNTkQGHqKyVPLdQ7jibyysM6S_q_FC35t-pHhZcM18DyJbqNBIdkj35Xvg7NwMm8c8kdjPt9JepEOrppC73eJML3xPJLGWSONLDDfFuQ=" rel="nofollow" target="_blank"><strong>NeuroStar@evolvemkd.com</strong></a></p>  <p>References</p>  <p>1 The effectiveness of SPRAVATO<sup>&#xAE; </sup>in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO<sup>&#xAE; </sup>does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO<sup>&#xAE;</sup>. For more important safety information about SPRAVATO<sup>&#xAE;</sup>, please visit <a href="https://www.globenewswire.com/Tracker?data=J_OU8SRuHNXE6O2upb69lWtbWuaFQFverv3EM4-zuWvTmOcbuEyh7pdOGulKFSqPspIOhaVn3B5mAcU95FR0lrKdRRX36nZUzghYM0RRRnPw4YnxkmJq5zZ4nov6E-gE3Wp89Dnc5Rwb4J89-adnU3-SLFdvmRbs7LXIwNBbaO9ZZRwepPWWFWmCq1YubLdxQ3iyZsWH9zrsSKtxdbTG30LKLYQ33A_eO1GUfYUteOCTXnLN3NR_lbmkJL-idglkjzO0LitT7mkD5efu1OxYhw==" rel="nofollow" target="_blank">spravatohcp.com</a>.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NDc2MiM3NTIxMTc1IzIxMTA0NDA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NmZmMjQ5MTYtODhjNi00ZTdjLWIwYTktNzQwNjJhZTliYjcyLTExMjIwMTEtMjAyNi0wNC0wNi1lbg==/tiny/Neuronetics.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/12db9039-d4bf-41a0-8b4a-324398e392b4"><img src="https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>

Neuronetics' CFO, Steven E. Pfanstiel, will leave the company on May 1, 2026. The company reaffirmed its previous financial guidance, which may help stabilize investor sentiment amid leadership changes.

Neuronetics Announces Chief Financial Officer Transition

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News